Philip Duncanson

Title: The Innovations of Philip Duncanson

Introduction

Philip Duncanson is a notable inventor based in London, GB. He has made significant contributions to the field of radiopharmaceuticals, holding a total of 3 patents. His work focuses on developing innovative compounds that enhance medical imaging and treatment.

Latest Patents

Duncanson's latest patents include the invention of N4 chelator conjugates. This invention provides tetra-amine chelator conjugates with biological targeting moieties, linked via a linker group and technetium complexes as radiopharmaceuticals. The design of the linker group allows for mono-functionalization at the bridgehead position, which provides both flexibility and minimizes lipophilicity and steric hindrance. Additionally, he has developed a contrast agent characterized by a specific formula that includes an organic group with binding affinity for angiotensin II receptor sites, along with a reporter moiety detectable in in vivo imaging.

Career Highlights

Throughout his career, Duncanson has worked with prominent companies such as Amersham Plc and GE Healthcare. His experience in these organizations has contributed to his expertise in the development of medical imaging technologies and radiopharmaceuticals.

Collaborations

Duncanson has collaborated with notable individuals in his field, including Harry John Wadsworth and Anthony Eamon Storey. These collaborations have likely enriched his research and innovation efforts.

Conclusion

Philip Duncanson's contributions to the field of radiopharmaceuticals and medical imaging are noteworthy. His innovative patents and collaborations reflect his commitment to advancing healthcare technology.